Grifols Plasma

Grifols Plasma is a prominent global healthcare entity specializing in plasma medicine and advanced biopharmaceutical solutions. Established in 2002, the company is dedicated to the collection of human plasma, which it then processes into vital therapies for individuals managing chronic, rare, and severe health conditions. Operating across the Biotechnology, Pharmaceuticals, and Healthcare sectors, Grifols Plasma supports healthcare professionals worldwide by fostering innovation in treatment development while rigorously maintaining high standards for operational safety and product quality.

With an extensive operational infrastructure, Grifols Plasma manages a broad network of plasma donation and processing centers. The company employs between 1,000-5,000 individuals across its 209 locations, demonstrating significant global reach and capacity. This robust network is fundamental to its mission of delivering essential plasma-derived medicines. To understand the team behind these critical operations, one can explore Meet Grifols Plasma's team. Their collective expertise is central to the company's ongoing commitment to patient well-being and therapeutic progress.

Generating $156.2M in revenue, Grifols Plasma holds a substantial position in the market. Its comprehensive product portfolio encompasses critical healthcare services, specialized medicines, diagnostic systems, and support for transfusion medicine and blood donation networks. Beyond its core plasma collection activities, Grifols Plasma actively contributes to hospitals, clinics, and research initiatives globally, solidifying its role as a key innovator in the biopharmaceutical field. The company's strategic emphasis on innovation and quality ensures continuous advancement in treatments for patients requiring specialized medical interventions.